Phibro Animal Health (PAHC) vs Rapport Therapeutics (RAPP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rapport Therapeutics (RAPP) has outperformed Phibro Animal Health (PAHC) over the past year, gaining 10.3% versus a gain of 0.8%. Phibro Animal Health is the larger company by market cap ($1.56 billion vs $1.46 billion), about 1.1 times the size. Phibro Animal Health pays a dividend yielding 1.25%, while Rapport Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PAHC | RAPP |
|---|---|---|
| Share price | $38.52 | $30.42 |
| Market cap | $1.56B | $1.46B |
| 1-day change | +2.99% | +1.89% |
| YTD return | +0.11% | -1.62% |
| 1-year return | +0.78% | +10.31% |
| 5-year return | +71.56% | — |
| P/E ratio (TTM) | 15.85 | — |
| Forward P/E | 10.03 | — |
| EPS (TTM) | $2.43 | $-3.03 |
| Dividend yield | 1.25% | 0.00% |
| Annual dividend | $0.48 | $0.00 |
| Revenue (latest FY) | $1.52B | — |
| Revenue growth (YoY) | +17.12% | — |
| Net income (latest FY) | $99.72M | $-111.48M |
| Gross margin | 33.76% | — |
| Operating margin | 12.81% | — |
| Net margin | 6.57% | — |
| 52-week high | $60.08 | $52.93 |
| 52-week low | $28.25 | $23.75 |
| Distance from 52-week high | -35.89% | -42.54% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +14.23% | +107.27% |
| Average volume | 236.19K | 358.42K |
| Shares outstanding | 21.11M | 47.98M |
| Employees | 2,605 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Phibro Animal Health offers a meaningfully higher dividend yield (1.25% vs 0.00%).
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
PAHC vs RAPP FAQ
Which is bigger, Phibro Animal Health or Rapport Therapeutics?
Phibro Animal Health (PAHC) is larger, with a market capitalization of $1.56B compared with $1.46B for Rapport Therapeutics (RAPP).
Which stock has performed better over the past year, PAHC or RAPP?
RAPP returned +10.31% over the past 12 months, compared with +0.78% for PAHC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Phibro Animal Health or Rapport Therapeutics?
Phibro Animal Health pays a dividend yielding 1.25%, while Rapport Therapeutics does not currently pay a regular dividend.
Are Phibro Animal Health and Rapport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.